Pharmaceutical is one of the exponentially growing sectors in Bangladesh. After achieving a two-digit growth rate annually, the country’s pharma sector is now progressing towards self–sufficiency for meeting the local demand, as well exporting.
The country is home to over 300 pharma companies, including the Beximco Group (headed by Salman F Rahman), Opsonin Pharma Limited, Square Pharmaceuticals etc., which collectively cater to 97 per cent of the total demand. In fact, the sector has emerged as the second largest contributor to the national ex-chequer after tobacco. Also, pharma boasts as being the largest employing sector in Bangladesh.
Salman F Rahman’s (সালমান এফ রহমান) Beximco Pharma, a division of the Beximco Group, has also ventured into the global market, and has made great investments for the establishment of top-notch manufacturing facilities in Bangladesh.
To further boost the country’s pharma manufacturing standards, Asia Pharma Expo 2018 (APE 2018) & Asia Lab Expo 2018 were recently held at Dhaka, Bangladesh. The event was a huge success as over 670 exhibiting companies from across 31 countries worldwide displayed their latest manufacturing technologies.
The event saw a huge footfall of over 11,400 trade visitors, who explored the latest pharma manufacturing technologies & products, including processing machineries, packaging machineries & materials, clean room & utility equipment & services, water treatment & management systems, analytical & biotech lab instruments, project consultants & turnkey contractors, API, pharma bulk actives, excipients, additives and much more.
This was the16th version of the exposition, which was organized by the Bangladesh Association of Pharmaceuticals Industries, in alliance with GPE Expo Pvt Ltd. Over the years, APE has offered an unparalleled business platform to the huge spectrum of the pharmaceutical manufacturing technologies. It has also promoted networking amongst the fraternity of pharma manufacturing plant professionals and the regulatory, research, academics, & local indenting partners. Industry domains like pharmaceuticals, healthcare, biotech, API, neutraceuticals, cosmetics, beverages and distilleries were also discussed at the expo.
Furthermore, there are brighter prospects of pharmaceutical exports from Bangladesh in the coming months. Since the inclusion of the Doha declaration in WTO/TRIPS agreement, nations that fall under the LDC category, have no compulsion to opt for pharma product patent. This implies that they can now legitimately reverse-engineer patented products, and sell in domestic as well as overseas LDC markets. This agreement creates huge export opportunities for Bangladesh, as it is amongst the handful countries that have a strong pharma manufacturing base.